New Drug Shows , Promising Results in Fight Against , Alzheimer's.
BBC reports that a new drug has been
hailed as a turning point in the battle
against Alzheimer's disease. .
A global trial confirmed that
donanemab, an antibody medicine,
can slow cognitive decline.
A global trial confirmed that
donanemab, an antibody medicine,
can slow cognitive decline.
This is truly a turning point in
the fight against Alzheimer's
and science is proving that it is
possible to slow down the disease, The Alzheimer's Society, via BBC.
BBC reports that the medicine proved
effective in the early stages of the disease
at clearing protein buildup in the brain. .
The trials suggest that the medication slowed
the pace of the disease by about a third, giving
patients more time to retain their mental capacities.
Eli Lilly produces donanemab, which works the same
way as competitor Eisai and Biogen's lecanemab,
which made global headlines by slowing the disease.
Eli Lilly produces donanemab, which works the same
way as competitor Eisai and Biogen's lecanemab,
which made global headlines by slowing the disease.
BBC points out that while the results
are promising, these medications are
not a risk-free form of treatment.
Up to a third of patients
reportedly experienced , brain swelling. .
Two volunteers, and potentially
a third, died after developing
dangerous swelling in the brain.
Regulators in Europe recently rejected another
Alzheimer's drug, aducanumab, citing safety
concerns and questions regarding the drug's efficacy
